.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,982,067

« Back to Dashboard

Details for Patent: 7,982,067

Title:Phenethanolamine derivatives for treatment of respiratory diseases
Abstract: Compounds of the formula (II) and (IV) are provided, which may be employed as intermediates for making compounds useful in treating respiratory diseases.
Inventor(s): Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Mann; Inderjit Singh (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB)
Assignee: Glaxo Group Limited (Greenford, Middlesex, GB)
Filing Date:Jul 14, 2010
Application Number:12/836,025
Claims:1. A compound of formula (II): ##STR00022## or a salt thereof, wherein m is an integer of from 2 to 8; n is an integer of from 2 to 5; with the proviso that m+n is 4 to 10; R.sup.1a, R.sup.2a, and R.sup.3a are each independently either the same as R.sup.1, R.sup.2, and R.sup.3 respectively as defined below or represent a precursor for said group R.sup.1, R.sup.2, or R.sup.3; R.sup.1 is selected from hydrogen, C.sub.1-6alkyl, hydroxy, halo, C.sub.1-6haloalkyl, --XC(O)NR.sup.9R.sup.10, --XNR.sup.8C(O)R.sup.9, --XNR.sup.8C(O)NR.sup.9R.sup.10, --XNR.sup.8SO.sub.2R.sup.9, --XSO.sub.2NR.sup.11R.sup.12, XNR.sup.8SO.sub.2R.sup.9R.sup.10, --XNR.sup.9R.sup.10, XN.sup.+R.sup.8R.sup.9R.sup.10, --XNR.sup.8C(O)OR.sup.9, --XCO.sub.2R.sup.9, --XNR.sup.8C(O)NR.sup.8C(O)NR.sup.9R.sup.10, --XSR.sup.9, XSOR.sup.9, and --XSO.sub.2R.sup.9; or R.sup.1 is selected from --X-aryl, --X-hetaryl, and --X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C.sub.1-6alkoxy, halo, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --NHC(O)(C.sub.1-6alkyl), --SO.sub.2(C.sub.1-6alkyl), --SO.sub.2(aryl), --SO.sub.2NH.sub.2, --SO.sub.2NH(C.sub.1-6alkyl), --SO.sub.2NH(C.sub.3-7cycloalkyl), --CO.sub.2H, --CO.sub.2(C.sub.1-6alkyl), --SO.sub.2NH(C.sub.3-7cycloalkylC.sub.1-6alkyl), --NH.sub.2, --NH(C.sub.1-6alkyl), or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy, C.sub.1-6alkoxy, halo, C.sub.1-6alkyl, or C.sub.1-6haloalkyl; X is --(CH.sub.2).sub.p-- or C.sub.2-6 alkenylene; p is an integer from 0 to 6, R.sup.8 and R.sup.9 are independently selected from hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, aryl, hetaryl, hetaryl(C.sub.1-6alkyl)- and aryl(C.sub.1-6alkyl)- and R.sup.8 and R.sup.9 are each independently optionally substituted by 1 or 2 groups independently selected from halo, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --NHC(O)(C.sub.1-6alkyl), --SO.sub.2(C.sub.1-6alkyl), --SO.sub.2(aryl), --CO.sub.2H, --CO.sub.2(C.sub.1-4alkyl), --NH.sub.2, --NH(C.sub.1-6alkyl), aryl(C.sub.1-6alkyl)-, aryl(C.sub.2-6alkenyl)-, aryl(C.sub.2-6alkynyl)-, hetaryl(C.sub.1-6alkyl)-, --NHSO.sub.2aryl, --NH(hetarylC.sub.1-6alkyl), --NHSO.sub.2hetaryl, --NHSO.sub.2(C.sub.1-6alkyl), --NHC(O)aryl, or --NHC(O)hetaryl: R.sup.10 is selected from hydrogen, C.sub.1-6alkyl and C.sub.3-7 cycloalkyl; R.sup.11 and R.sup.12 are independently selected from hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, aryl, hetaryl, hetaryl(C.sub.1-6alkyl)- and aryl(C.sub.1-6alkyl)-, or R.sup.11 and R.sup.12, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring; and R.sup.11 and R.sup.12 are each optionally substituted by one or two groups independently selected from halo, C.sub.1-6alkyl, and C.sub.1-6haloalkyl; where R.sup.1 is --XNR.sup.8C(O)NR.sup.9R.sup.10, R.sup.8 and R.sup.9 may, together with the --NC(O)N-- portion of the group R.sup.1 to which they are bonded, form a 5-, 6- or 7-membered saturated or unsaturated ring; where R.sup.1 is --XNR.sup.8C(O)OR.sup.9, R.sup.8 and R.sup.9 may, together with the --NC(O)O-- portion of the group R.sup.1 to which they are bonded, form a 5-, 6- or 7-membered saturated or unsaturated ring; where R.sup.1 is --XC(O)NR.sup.9R.sup.10 or --XNR.sup.8C(O)NR.sup.9R.sup.10, R.sup.9 and R.sup.10 may, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring; R.sup.2 is selected from hydrogen, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo, aryl, aryl(C.sub.1-6alkyl)-, C.sub.1-6haloalkoxy, and C.sub.1-6 haloalkyl; R.sup.3 is selected from hydrogen, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo, aryl, aryl(C.sub.1-6alkyl)-, C.sub.1-6haloalkoxy, and C.sub.1-6haloalkyl; R.sup.4 and R.sup.5 are independently selected from hydrogen and C.sub.1-4 alkyl with the proviso that the total number of carbon atoms in R.sup.4 and R.sup.5 is not more than 4; and, R.sup.6 and R.sup.7 are independently selected from hydrogen and C.sub.1-4alkyl with the proviso that the total number of carbon atoms in R.sup.6 and R.sup.7 is not more than 4; and R.sup.13, R.sup.14, and R.sup.15 are each independently either hydrogen or a protecting group provided that at least one of R.sup.13, R.sup.14, and R.sup.15 is a protecting group, and R.sup.19 is hydrogen or a protecting group.

2. A compound of formula (II) according to claim 1 or a salt thereof wherein R.sup.1 is selected from hydrogen, C.sub.1-6alkyl, hydroxy, halo, C.sub.1-6haloalkyl, --XNR.sup.8(C)OR.sup.9, --XNR.sup.8C(O)NR.sup.9R.sup.10, --XNR.sup.8SO.sub.2R.sup.9, --XSO.sub.2NR.sup.11R.sup.12, --XNR.sup.9R.sup.10, --XNR.sup.8C(O)OR.sup.9, XSR.sup.9, XSOR.sup.9, XSO.sub.2R.sup.9, or from X-aryl, X-hetaryl or X-aryloxy, optionally substituted.

3. A compound of formula (II) according to claim 1 or a salt thereof wherein X is (CH.sub.2).sub.p wherein p is zero.

4. A compound of formula (II) according to claim 1 or a salt thereof wherein R.sup.1 is selected from hydrogen, C.sub.1-4alkyl, hydroxy, halo, --NR.sup.8C(O)NR.sup.9R.sup.10, and --NR.sup.8SO.sub.2R.sup.9.

5. A compound of formula (II) according to claim 1 or a salt thereof wherein R.sup.2 and R.sup.3 are independently selected from hydrogen, halogen, haloC.sub.1-6alkyl, C.sub.1-6alkyl, and phenyl or substituted phenyl.

6. A compound of formula (II) according to claim 1 or a salt thereof wherein R.sup.1 is not XNR.sup.8SO.sub.2R.sup.9R.sup.10, XN.sup.+R.sup.8R.sup.9R.sup.10, --XCO.sub.2R.sup.9, --XNR.sup.8C(O)NR.sup.8C(O)NR.sup.9R.sup.10, --XSR.sup.9, XSOR.sup.9, or --XSO.sub.2R.sup.9.

7. A compound of formula (II) according to claim 1 or a salt thereof wherein the group R.sup.1 is attached to the meta-position relative to the --OCR.sup.6R.sup.7-- link.

8. A compound of formula (II) according to claim 1 or a salt thereof wherein the groups R.sup.2 and R.sup.3 are each independently attached to the ortho-position relative to the --OCR.sup.6R.sup.7-link.

9. A compound of formula (II) according to claim 8 or a salt thereof wherein R.sup.1 represents a substituent other than hydrogen, attached to the meta-position relative to the --OCR.sup.6R.sup.7-link, and R.sup.2 and R.sup.3 each represent hydrogen.

10. A compound of formula (II) according to claim 1 or a salt thereof wherein R.sup.1 represents hydrogen and R.sup.2 and R.sup.3 each represent a substituent at least one of which is other than hydrogen, and R.sup.2 and R.sup.3 are each independently attached to the ortho- or meta-positions relative to the --OCR.sup.6R.sup.7-link.

11. A compound of formula (II) according to claim 10, or a salt thereof, wherein R.sup.2 and R.sup.3 each represent halogen attached to the ortho position relative to the --OCR.sup.6R.sup.7-link.

12. A compound of formula (II) according to claim 1 or a salt thereof wherein R.sup.4 and R.sup.5 are independently selected from hydrogen and methyl.

13. A compound of formula (II) according to claim 1 or a salt thereof wherein R.sup.6 and R.sup.7 are independently selected from hydrogen and methyl.

14. A compound of formula (II) according to claim 1 or a salt thereof wherein m is 4, 5 or 6, and n is 2 or 3.

15. A compound according to claim 1 wherein R.sup.13 and R.sup.14 together represent a protecting group R.sup.16R.sup.17C.dbd. as in the compound of formula (III): ##STR00023## or a salt thereof, wherein R.sup.1a, R.sup.2a, R.sup.3a, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, m, and n are as defined for the compound of formula (II).

16. A compound selected from the group consisting of: N-[3-({2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyeth- yl]amino}hexyl)oxy]ethoxy}methyl)phenyl]-N'-phenylurea; and (1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-(2,2-dimethy- l-4H-1,3-benzodioxin-6-yl)ethanol; N-cyclohexyl-N'-[3-({2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl- )-2-hydroxyethyl]amino}hexyl)oxy]ethoxy}methyl)phenyl]urea; N-(1,1'-biphenyl-4-yl)-N'-[3-({2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzod- ioxin-6-yl)-2-hydroxyethyl]amino}hexyl)oxy]ethoxy}methyl)phenyl]urea; N-cyclopropyl-3'-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-- 2-hydroxyethyl]amino}hexyl)oxy]ethoxy)methyl]-1,1'-biphenyl-2-sulfonamide; (1R)-2-{[6-(2-[{3-(2,3-dihydroimidazo[2,1-b][1,3]thiazol-6-ylmethyl)amino- ]-phenyl}methoxy]ethoxy)hexyl]amino}-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-- yl)ethanol; N-{3-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyeth- yl]-amino}hexyl)oxy]ethoxy)methyl]phenyl}-3-[(phenylsulfonyl)amino]benzami- de; N-(3-{[({3-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-h- ydroxy-ethyl]amino}hexyl)oxy]ethoxy)methyl]phenyl}amino)carbonyl]amino}phe- nyl)-pyridine-3-carboxamide; N-cyclohexyl-3-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-- hydroxyethyl]amino}hexyl)oxy]ethoxy)methyl]-N-({[2-(trimethylsilyl)ethyl]-- oxy}methyl)benzenesulfonamide; 3'-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethyl- ]-amino}hexyl)oxy]ethoxy)methyl]-1,1'-biphenyl-3-ol; (1R)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-[(6-{2-[(3-iodobenzyl)oxy- ]-ethoxy}hexyl)amino]ethanol; N-{3-[(2-{[6-({(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}- -amino)hexyl]oxy}ethoxy)methyl]phenyl}-N'-[3-(phenylethynyl)phenyl]urea; (1R)-2-{[6-(2-{[3'-{2,4-bis[(1,1-dimethylethyl)oxy]pyrimidin-5-yl}-1,1'-b- iphenyl-3-yl]methoxy}ethoxy)hexyl]amino}-1-(2,2-dimethyl-4H-1,3-benzodioxi- n-6-yl)ethanol; and cyclopentyl 3-[(2-[(6-{[(2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxy-ethyl- ]amino}hexyl)oxy]ethoxy)methyl]phenylcarbamate.

17. A compound of formula (IV): ##STR00024## or a salt thereof, wherein m is an integer of from 2 to 8; n is an integer of from 2 to 5; with the proviso that m+n is 4 to 10; R.sup.1a, R.sup.2a, and R.sup.3a are each independently either the same as R.sup.1, R.sup.2, and R.sup.3 respectively as defined below or represent a precursor for said group R.sup.1, R.sup.2, or R.sup.3; R.sup.1 is selected from hydrogen, C.sub.1-6alkyl, hydroxy, halo, C.sub.1-6haloalkyl, --XC(O)NR.sup.9R.sup.10, --XNR.sup.8C(O)R.sup.9, --XNR.sup.8C(O)NR.sup.9R.sup.10, --XNR.sup.8SO.sub.2R.sup.9, --XSO.sub.2NR.sup.11R.sup.12, XNR.sup.8SO.sub.2R.sup.9R.sup.10, --XNR.sup.9R.sup.10, XN.sup.+R.sup.8R.sup.9R.sup.10, --XNR.sup.8C(O)OR.sup.9, --XCO.sub.2R.sup.9, --XNR.sup.8C(O)NR.sup.8C(O)NR.sup.9R.sup.10, --XSR.sup.9, XSOR.sup.9, and --XSO.sub.2R.sup.9; or R.sup.1 is selected from --X-aryl, --X-hetaryl, and --X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C.sub.1-6alkoxy, halo, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --NHC(O)(C.sub.1-6alkyl), --SO.sub.2(C.sub.1-6alkyl), --SO.sub.2(aryl), --SO.sub.2NH.sub.2, --SO.sub.2NH(C.sub.1-6alkyl), --SO.sub.2NH(C.sub.3-7cycloalkyl), --CO.sub.2H, --CO.sub.2(C.sub.1-6alkyl), --SO.sub.2NH(C.sub.3-7cycloalkylC.sub.1-6alkyl), --NH.sub.2, --NH(C.sub.1-6alkyl), or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy, C.sub.1-6alkoxy, halo, C.sub.1-6alkyl, or C.sub.1-6haloalkyl; X is --(CH.sub.2).sub.p-- or C.sub.2-6 alkenylene; p is an integer from 0 to 6, R.sup.8 and R.sup.9 are independently selected from hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, aryl, hetaryl, hetaryl(C.sub.1-6alkyl)- and aryl(C.sub.1-6alkyl)- and R.sup.8 and R.sup.9 are each independently optionally substituted by 1 or 2 groups independently selected from halo, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --NHC(O)(C.sub.1-6alkyl), --SO.sub.2(C.sub.1-6alkyl), --SO.sub.2(aryl), --CO.sub.2H, --CO.sub.2(C.sub.1-4alkyl), --NH.sub.2, --NH(C.sub.1-6alkyl), aryl(C.sub.1-6alkyl)-, aryl(C.sub.2-6alkenyl)-, aryl(C.sub.2-6alkynyl)-, hetaryl(C.sub.1-6alkyl)-, --NHSO.sub.2aryl, --NH(hetarylC.sub.1-6alkyl), --NHSO.sub.2hetaryl, --NHSO.sub.2(C.sub.1-6alkyl), --NHC(O)aryl, or --NHC(O)hetaryl: R.sup.10 is selected from hydrogen, C.sub.1-6alkyl and C.sub.3-7 cycloalkyl; R.sup.11 and R.sup.12 are independently selected from hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, aryl, hetaryl, hetaryl(C.sub.1-6alkyl)- and aryl(C.sub.1-6alkyl)-, or R.sup.11 and R.sup.12, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring; and R.sup.11 and R.sup.12 are each optionally substituted by one or two groups independently selected from halo, C.sub.1-6alkyl, and C.sub.1-6haloalkyl; where R.sup.1 is --XNR.sup.8C(O)NR.sup.9R.sup.10, R.sup.8 and R.sup.9 may, together with the --NC(O)N-- portion of the group R.sup.1 to which they are bonded, form a 5-, 6- or 7-membered saturated or unsaturated ring; where R.sup.1 is --XNR.sup.8C(O)OR.sup.9, R.sup.8 and R.sup.9 may, together with the --NC(O)O-- portion of the group R.sup.1 to which they are bonded, form a 5-, 6- or 7-membered saturated or unsaturated ring; where R.sup.1 is --XC(O)NR.sup.9R.sup.10 or --XNR.sup.8C(O)NR.sup.9R.sup.10, R.sup.9 and R.sup.10 may, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring; R.sup.2 is selected from hydrogen, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo, aryl, aryl(C.sub.1-6alkyl)-, C.sub.1-6haloalkoxy, and C.sub.1-6 haloalkyl; R.sup.3 is selected from hydrogen, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkoxy, halo, aryl, aryl(C.sub.1-6alkyl)-, C.sub.1-6haloalkoxy, and C.sub.1-6haloalkyl; R.sup.4 and R.sup.5 are independently selected from hydrogen and C.sub.1-4 alkyl with the proviso that the total number of carbon atoms in R.sup.4 and R.sup.5 is not more than 4; and, R.sup.6 and R.sup.7 are independently selected from hydrogen and C.sub.1-4alkyl with the proviso that the total number of carbon atoms in R.sup.6 and R.sup.7 is not more than 4; and R.sup.13, R.sup.14, and R.sup.15 are each independently either hydrogen or a protecting group provided that at least one of R.sup.13, R.sup.14, and R.sup.15 is a protecting group, and R.sup.19 is hydrogen or a protecting group.

18. A compound selected from the group consisting of: (5R)-3-(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)-5-(2,2-dimethyl-4H-1,- 3-benzodioxin-6-yl)-1,3-oxazolidin-2-one; (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-(6-{2-[(3-nitrobenzyl)oxy- ]-ethoxy}hexyl)-1,3-oxazolidin-2-one; N-(3-{[2-({6-[(5R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxa- zolidin-3-yl]hexyl}oxy)ethoxy]methyl}phenyl)-N'-phenylurea; N-cyclohexyl-M-(3-{[2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-- 2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy]methyl}phenyl)urea; N-(1,1'-biphenyl-4-yl)-N'-(3-{[2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodi- oxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy]methyl}phenyl)urea; (5R)-3-(6-{2-[(3-aminobenzyl)oxy]ethoxy}hexyl)-5-(2,2-dimethyl-4H-1,3-ben- zodioxin-6-yl)-1,3-oxazolidin-2-one; (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-{6-[2-{[(3-nitrophenyl)-m- ethyl]oxy}ethoxy]hexyl}-1,3-oxazolidin-2-one; N-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxa- zolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]-3-[(phenylsulfonyl)amino]-ben- zamide; 3-amino-N-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl- )-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]benzamide; N-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxa- zolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]-3-nitrobenzamide; N-(3-aminophenyl)-N'-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-- 6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]urea; N-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxa- zolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]-N'-(3-nitrophenyl)urea; N-cyclohexyl-3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-o- xo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)-N-({[2-(trimethylsilyl)eth- yl]oxy}-methyl)benzenesulfonamide; N-{3-[({[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1- ,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]amino}carbonyl)amino]-ph- enyl}pyridine-3-carboxamide; cyclopentyl 3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazol- idin-3-yl]hexyl}oxy)ethoxy}methyl)phenylcarbamate; N-[3-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxa- zolidin-3-yl]hexyl}oxy)ethoxy}methyl)phenyl]-N'-[3-(phenylethynyl)phenyl]u- rea; 1,1-dimethylethyl cyclopropyl{[3'-({2-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-- oxo-1,3-oxazolidin-3-yl]hexyl}oxy)ethoxy}methyl)-1,1'-biphenyl-2-yl]sulfon- yl}carbamate; (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-(6-{2-([3-(4,4,5,5-tetram- ethyl-1,3,2-dioxaborolan-2-yl)phenyl]methoxy)ethoxy}hexyl)-1,3-oxazolidin-- 2-one; (5R)-3-[6-(2-[{3-[(2,3-dihydroimidazo[2,1-b][1,3]thiazol-6-ylmethyl- )amino]-phenyl}methoxy]ethoxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-- yl)-1,3-oxazolidin-2-one; (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-{6-[2-{(3-iodophenyl)meth- oxy}ethoxy]hexyl}-1,3-oxazolidin-2-one; (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-{6-[2-{(3'-hydroxy-1,1'-b- iphenyl-3-yl)methoxy}ethoxy]hexyl}-1,3-oxazolidin-2-one; and (5R)-3-{6-[2-{(3'-{2,4-bis[(1,1-dimethylethyl)oxy]pyrimidin-5-yl}-1,1'-bi- phenyl-3-yl)methoxy}ethoxy]hexyl}-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)- -1,3-oxazolidin-2-one.

19. A compound according to claim 17 wherein R.sup.13 and R.sup.14 are independently selected from an ester.

20. A compound according to claim 17 wherein R.sup.15 represents a group selected from benzyl, .alpha.-methylbenzyl, diphenylmethyl, triphenylmethyl, benzyloxycarbonyl, tert-butoxycarbonyl, trichloroacetyl, and trifluoroacetyl.

21. A compound of according to claim 17 wherein R.sup.19 represents a trialkylsilyl group.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc